Initial combination therapy in early Crohn's disease

The Lancet

Volumn 371, Issue 9613, 2008, Pages 635-636

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; INFLIXIMAB; METHOTREXATE; PREDNISONE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORTICOSTEROID THERAPY; CROHN DISEASE; DEMYELINATION; DRUG MEGADOSE; DRUG SAFETY; ENDOSCOPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 39449131142     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60285-8     Document Type: Note

References (10)

1. D'Haens G., Baert F., van Assche G., et al., for the Belgian Inflammatory Bowel Disease Research Group and the North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008) 660-667
2. Hanauer S., Feagan B., Lichtenstein G., et al., the ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
3. Targan S., Hanauer S., van Deventer S., and for The Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
4. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
5. Lichtenstein G., Abreu M., Cohen R., and Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 (2006) 940-987
6. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., and Gendre J. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54 (2005) 237-241
7. Lichtenstein G., Feagan B., Cohen R., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 (2006) 621-630
8. Toruner M, Loftus EV, Harmsen WS JF, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (in press).
9. Goekoop-Ruiterman Y., de Vries-Bouwstra J., Allaart C., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146 (2007) 406-415
10. Study of biologic and immunomodulator naive patients in Crohn's disease (January 8, 2008). http://www.controlled-trials.com/mrct/trial/67575/sonic (accessed Jan 10, 2008).